( Nasdaq : MITI ) , a biopharmaceutical company developing novel , proprietary antibodies for the treatment of cancer , inflammation and autoimmune diseases , today announced that it is regaining from its partner MedImmune the rights in North America to its most advanced BiTE antibody candidate , blinatumomab , also known as MT103 .